Vijay Ramakrishnan

Vijay Ramakrishnan

Covance Laboratories - Princeton / United States
Medical and Health Sciences / Immunology
AD Scientific Index ID: 4532233
-
person_outline Vijay Ramakrishnan's MOST POPULAR ARTICLES
1-) Bortezomib combination therapy in multiple myelomaP Kapoor, V Ramakrishnan, SV RajkumarSeminars in hematology 49 (3), 228-242, 20121072012
2-) Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, JL Haug, TK Kimlinger, LE Wellik, TE Witzig, ...Oncogene 29 (8), 1190-1202, 20101052010
3-) PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promiseV Ramakrishnan, S KumarLeukemia & lymphoma 59 (11), 2524-2534, 2018822018
4-) TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsV Ramakrishnan, T Kimlinger, J Haug, M Timm, L Wellik, T Halling, ...American journal of hematology 85 (9), 675-686, 2010822010
5-) MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin\'s lymphomaV Ramakrishnan, S Ansell, J Haug, D Grote, T Kimlinger, M Stenson, ...Leukemia 26 (2), 340-348, 2012792012